Safety and utility of kidney biopsy in patients with estimated glomerular filtration rate < 30 ml/min/1.73 m2.

Kidney biopsy (KBx) is the gold standard for evaluation of kidney disease, but is associated with a higher risk of complications in patients with reduced glomerular filtration rate (GFR). We studied the safety and utility of KBx in patients with eGFR <30 ml/min/1.73 m2 . METHODS Consecutive adult patients with eGFR <30 ml/min/1.73 m2 , who were planned for a KBx and consented to participate were prospectively enrolled. Patients with solitary/transplant kidney or acute kidney injury were excluded. Haemoglobin was checked on the day of KBx and repeated 18-24 h later along with a screening ultrasound. Post-KBx complications were noted and their risk-factors analysed. The utility of the KBx was graded as effecting significant, some, or no change to subsequent management. RESULTS Of the 126 patients included, 75% were male, 27.7% were diabetic, and the median eGFR was 13.5 ml/min/1.73m2 . Major complications occurred in 5.6%. Peri-renal haematomas were detected in 37.3%, and haematomas ≥2 cm were significantly more frequent in those with eGFR <15 ml/min/1.73 m2 (29.2% vs. 13%, p = .032). Dialysis was a risk factor, while pre KBx blood transfusion, diabetes and higher serum albumin were protective against any complication. KBx was more likely to make a significant difference in management in those with eGFR 15-29 ml/min/1.73m2 (44.1% vs. 11.1%, p < .001). Increasing age, lower serum creatinine and albumin were independently associated with KBx utility. CONCLUSION KBx is relatively safe in severe kidney disease but its risk to benefit balance needs to be carefully considered when eGFR is <15 ml/min/1.73m2 . This article is protected by copyright. All rights reserved.

[1]  L. Fauchier,et al.  Major Bleeding and Risk of Death after Percutaneous Native Kidney Biopsies: A French Nationwide Cohort Study. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[2]  S. Waikar,et al.  Bleeding Complications After Percutaneous Native Kidney Biopsy: Results From the Boston Kidney Biopsy Cohort , 2020, Kidney international reports.

[3]  M. Segelmark,et al.  Clinical parameters predicting complications in native kidney biopsies , 2019, Clinical kidney journal.

[4]  C. Vecchione,et al.  The Main Determinants of Diabetes Mellitus Vascular Complications: Endothelial Dysfunction and Platelet Hyperaggregation , 2018, International journal of molecular sciences.

[5]  W. Peng,et al.  Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy , 2018, Kidney and Blood Pressure Research.

[6]  Shankar Prinja,et al.  Cost of hemodialysis in a public sector tertiary hospital of India , 2018, Clinical kidney journal.

[7]  H. Sugiyama,et al.  Arterial Stiffness is an Independent Risk Factor for Anemia After Percutaneous Native Kidney Biopsy , 2017, Kidney and Blood Pressure Research.

[8]  N. Prasad,et al.  Real-time ultrasound-guided percutaneous renal biopsy with needle guide by nephrologists decreases post-biopsy complications , 2015, Clinical kidney journal.

[9]  S. Doucette,et al.  Percutaneous native renal biopsy adequacy: a successful interdepartmental quality improvement activity , 2015, Canadian journal of kidney health and disease.

[10]  W. Whittier,et al.  Percutaneous Renal Biopsy of Native Kidneys: A Single-Center Experience of 1,055 Biopsies , 2014, American Journal of Nephrology.

[11]  A. Lupo,et al.  Renal Biopsy in Chronic Kidney Disease: Lessons from a Large Italian Registry , 2013, American Journal of Nephrology.

[12]  L. Bostad,et al.  Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[13]  Ethan M Balk,et al.  Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  W. Whittier,et al.  Complications of the percutaneous kidney biopsy. , 2012, Advances in chronic kidney disease.

[15]  S. Agarwal,et al.  What do we know about chronic kidney disease in India: first report of the Indian CKD registry , 2012, BMC Nephrology.

[16]  T. Kovács,et al.  Histological Diagnosis Determines Complications of Percutaneous Renal Biopsy: A Single-Center Experience in 353 Patients , 2011, Kidney and Blood Pressure Research.

[17]  A. Joseph,et al.  Utility of percutaneous renal biopsy in chronic kidney disease , 2010, Nephrology.

[18]  E. Lewis,et al.  The value of post-biopsy ultrasound in predicting complications after percutaneous renal biopsy of native kidneys. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  E. Elghoroury,et al.  Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[20]  Shinsuke Nomura,et al.  Ultrasonography as a predictor of overt bleeding after renal biopsy , 2009, Clinical and Experimental Nephrology.

[21]  S. Varughese,et al.  Pre-tertiary hospital care of patients with chronic kidney disease in India. , 2007, The Indian journal of medical research.

[22]  L. Gesualdo,et al.  Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. , 2004, Kidney international.

[23]  K. Tsuchiya,et al.  New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels. , 2001, Blood.

[24]  S. White,et al.  A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. , 2000, Kidney international.

[25]  E. Sloand,et al.  Studies on platelet membrane glycoproteins and platelet function during hemodialysis. , 1997, Journal of the American Society of Nephrology : JASN.

[26]  R. Hakim,et al.  Defective platelet aggregation in uremia is transiently worsened by hemodialysis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  A. Parrish Complications of percutaneous renal biopsy: a review of 37 years' experience. , 1992, Clinical nephrology.

[28]  K. Farrington,et al.  Renal biopsy in patients with unexplained renal impairment and normal kidney size. , 1989, The Quarterly journal of medicine.

[29]  F. Molinas,et al.  The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. , 1970, The American journal of medicine.

[30]  J. White,et al.  Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. , 1970, The American journal of medicine.

[31]  W. Whittier,et al.  Timing of complications in percutaneous renal biopsy. , 2004, Journal of the American Society of Nephrology : JASN.

[32]  J. Cameron,et al.  The introduction of renal biopsy into nephrology from 1901 to 1961: a paradigm of the forming of nephrology by technology. , 1997, American journal of nephrology.

[33]  L. Jeyaseelan,et al.  Nondiabetic renal disease in noninsulin-dependent diabetics in a south Indian Hospital. , 1994, Nephron.

[34]  D. Adu,et al.  Knowledge of renal histology alters patient management in over 40% of cases. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  J. Joist,et al.  Potentiation by red blood cells of shear-induced platelet aggregation: relative importance of chemical and physical mechanisms. , 1984, Blood.